Evaluation of three influenza neuraminidase inhibition assays for use in a public health laboratory setting during the 2011-2012 influenza season

Public Health Reports

Volumn 128, Issue SUPPL. 2, 2013, Pages 75-87

  Murtaugh, William ^a,b   Mahaman, Lalla ^a   Healey, Benjamin ^a   Peters, Heather ^a   Anderson, Barbara ^a   Tran, Mandy ^a   Ziese, Marci ^a   Paz Carlos, Maria ^a,b  

^a MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; SIALIDASE;

2009 H1N1 INFLUENZA; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG DETERMINATION; DRUG SCREENING; HIGH THROUGHPUT SCREENING; IC 50; INFLUENZA A (H3N2); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; WILD TYPE; DIAGNOSTIC PROCEDURE; DRUG EFFECT; ENZYMOLOGY; EVALUATION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; METHODOLOGY; PUBLIC HEALTH; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL LABORATORY TECHNIQUES; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MARYLAND; NEURAMINIDASE; OSELTAMIVIR; PUBLIC HEALTH; ZANAMIVIR;

EID: 84887372756     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/00333549131280s212     Document Type: Article

References (21)

1. Food and Drug Administration (US). Influenza (fu) antiviral drugs and related information [cited 2012 Jul 16]. Available from: URL: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm100228.htm#ApprovedDrugs
2. GlaxoSmithKline. Relenza™: highlights of prescribing information. Research Triangle Park (NC): GlaxoSmithKline; 2011. Also available from: URL: http://us.gsk.com/products/assets/us_relenza.pdf [cited 2012 May 7].
3. Roche Laboratories Inc. Tamifu® (oseltamivir phosphate) capsules and for oral suspension. Nutley (NJ): Roche Laboratories Inc.; 2008. Also available from: URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021087s047,%20021246s033lbl.pdf [cited 2012 May 7].
4. Sorbello A, Jones SC, Carter W, Struble K, Boucher R, Truffa M, et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin Infect Dis 2012;55:1-7.
5. Hurt AC, Holien JK, Parker MW, Barr IG. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic, and highly pathogenic influenza viruses. Drugs 2009;69:2523-2531.
6. Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011;11:134.
7. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009;58(35):969-972.
8. Centers for Disease Control and Prevention (US). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immu-nosuppressed patients-Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009;58(32):893-896.
9. Le QM, Wertheim H, Tran ND, van Doorn HR, Nguyen TH, Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010;362:86-87.
10. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther 2012;17(1 Pt B):159-173.
11. Update: influenza activity-United States, 2011-12 season and composition of the 2012-13 influenza vaccine. MMWR Morb Mortal Wkly Rep 2012;61(22):414-420.
12. Centers for Disease Control and Prevention (US). 2011-2012 fu season draws to a close [cited 2012 Jun 11]. Available from: URL: http://www.cdc.gov/fu/spotlights/2011-2012-fu-season-wrapup.htm
13. Life Technologies Corporation. Applied Biosystems® NA-Star® influenza neuraminidase inhibitor resistance detection kit protocol. Foster City (CA): Applied Biosystems; 2006.
14. Life Technologies Corporation. Applied Biosystems NA-XTD™ influenza neuraminidase assay kit protocol. Foster City (CA): Life Technologies Corporation; 2010.
15. Life Technologies Corp. Applied Biosystems NA-Fluor™ influenza neuraminidase assay kit protocol. Foster City (CA): Life Technologies Corporation; 2010.
16. Wetherall NT, Trivedi T, Zeller J, Hodges-Savola C, McKimm-Breschkin JL, Zambon M, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the Neuraminidase Inhibitor Susceptibility Network. J Clin Microbiol 2003;41:742-750.
17. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008;52:3284-3292.
18. Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2010;2:2269-2289.
19. International Society for Infuenza and Other Respiratory Viruses (Isirv) Antiviral Group. Panel of infuenza A and B viruses for assessment of neuraminidase inhibitor susceptibility. 2012 [cited 2012 Jun 18]. Available from: URL: http://www.isirv.org/site/images/stories/avg_documents/Resistance/avg%20leafet%20nov12.pdf
20. Centers for Disease Control and Prevention (US). JASPR: Version 1.2. Atlanta: CDC; 2011.
21. International Society for Influenza and Other Respiratory Viruses (Isirv) Antiviral Group. Analysis of IC50 data [cited 2012 Jun 18]. Available from: URL: http://isirv.org/site/index.php /methodology/analysis-of-ic50-data